STOCK TITAN
  1. Home
  2. Sec-filings
  3. NBP
  4. [Form 3] NovaBridge Biosciences Initial Statement of Beneficial Ownership

NovaBridge Biosciences (NBP) director reports 2024 and 2025 option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

NovaBridge Biosciences director Yang Conor Chia-hung filed an initial ownership report showing two employee stock option positions tied to the company’s Ordinary Shares. One 2024 option covers 114,093 underlying Ordinary Shares at an exercise price of $1.22 per ADS-equivalent, expiring on October 1, 2034, and is fully vested and exercisable. A 2025 option covers 34,530 underlying Ordinary Shares at an exercise price of $3.86 per ADS-equivalent, expiring on October 1, 2035, and will vest in full on the first anniversary of its October 1, 2025 grant date. Footnotes note that the Ordinary Shares may be represented by ADSs, with each 10 ADSs representing 23 Ordinary Shares.

Positive

  • None.

Negative

  • None.
Insider Yang Conor Chia-hung
Role Director
Type Security Shares Price Value
holding 2024 Employee Share Option (right to buy) -- -- --
holding 2025 Employee Share Option (right to buy) -- -- --
Holdings After Transaction: 2024 Employee Share Option (right to buy) — 114,093 shares (Direct); 2025 Employee Share Option (right to buy) — 34,530 shares (Direct)
Footnotes (1)
  1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. Number of underlying secuities and exercise price expressed in terms of ADSs. The option was granted on October 1, 2024 and is fully vested and exercisable. The option was granted on October 1, 2025. The option vests and becomes exercisable in full on the first anniversary of the option's grant date.
2024 option underlying shares 114,093 Ordinary Shares Underlying Ordinary Shares for 2024 Employee Share Option
2024 option exercise price $1.22 per ADS-equivalent Exercise price for 2024 Employee Share Option
2025 option underlying shares 34,530 Ordinary Shares Underlying Ordinary Shares for 2025 Employee Share Option
2025 option exercise price $3.86 per ADS-equivalent Exercise price for 2025 Employee Share Option
2024 option expiration October 1, 2034 Expiration date of 2024 Employee Share Option
2025 option expiration October 1, 2035 Expiration date of 2025 Employee Share Option
American Depositary Shares financial
"The Ordinary Shares may be represented by American Depositary Shares ("ADS")."
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
exercise price financial
"Number of underlying secuities and exercise price expressed in terms of ADSs."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested and exercisable financial
"The option was granted on October 1, 2024 and is fully vested and exercisable."
underlying securities financial
"Number of underlying secuities and exercise price expressed in terms of ADSs."
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Yang Conor Chia-hung
(Last)(First)(Middle)
C/O NOVABRIDGE BIOSCIENCES,
2440 RESEARCH BOULEVARD, SUITE 400
(Street)
ROCKVILLE MARYLAND 20850
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
2024 Employee Share Option (right to buy) (3)10/01/2034Ordinary Shares(1)114,093(2)$1.22(2)D
2025 Employee Share Option (right to buy) (4)10/01/2035Ordinary Shares(1)34,530(2)$3.86(2)D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
2. Number of underlying secuities and exercise price expressed in terms of ADSs.
3. The option was granted on October 1, 2024 and is fully vested and exercisable.
4. The option was granted on October 1, 2025. The option vests and becomes exercisable in full on the first anniversary of the option's grant date.
Remarks:
Exhibit List: Ex. 24.1 - Power of Attorney
/s/ Xi-Yong (Sean) Fu as attorney-in-fact04/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the NovaBridge Biosciences (NBP) Form 3 filing show for Yang Conor Chia-hung?

The Form 3 shows Yang Conor Chia-hung’s initial ownership of employee stock options in NovaBridge Biosciences. It lists two option grants over Ordinary Shares, including their underlying share counts, exercise prices, vesting terms, and expiration dates, but no open-market buy or sell transactions.

How many shares underlie Yang Conor Chia-hung’s 2024 stock option in NovaBridge Biosciences (NBP)?

The 2024 employee share option covers 114,093 underlying Ordinary Shares of NovaBridge Biosciences. The option is fully vested and exercisable and carries an exercise price expressed as $1.22 per ADS-equivalent, with an expiration date of October 1, 2034 according to the filing footnotes.

What are the key terms of the 2025 stock option reported for NovaBridge Biosciences (NBP)?

The 2025 employee share option covers 34,530 underlying Ordinary Shares with an exercise price of $3.86 per ADS-equivalent. It was granted on October 1, 2025, vests in full on the first anniversary of that grant date, and expires on October 1, 2035, as disclosed.

Are the NovaBridge Biosciences (NBP) options held by Yang Conor Chia-hung vested yet?

The 2024 option is fully vested and exercisable as of the filing. The 2025 option was granted on October 1, 2025 and will vest and become exercisable in full on the first anniversary of that grant date, based on the footnote disclosure.